Risedronate Sodium(rah sed’ dro nate)
Actonel, AtelviaDNC
PREGNANCY CATEGORY C
Drug Class
Bisphosphonate
Therapeutic Actions
Affects osteoclast activity by reducing the enzymatic and transport processes that lead to resorption of the bone and by inhibiting the osteoclast proton pump, leading to a rate of bone turnover near normal in patients with Paget disease and decreasing the elevated rate of bone turnover in postmenopausal osteoporosis.
Indications
-
Treatment of Paget disease of bone
-
Treatment and prevention of osteoporosis in postmenopausal women
-
Treatment and prevention of glucocorticoid-induced osteoporosis
-
To increase bone mass in men with osteoporosis
Contraindications and Cautions
-
Contraindicated with allergy to bisphosphonates; severe renal disease, hypocalcemia, inability to stand or sit upright for at least 30 min, esophageal abnormalities that delay esophageal emptying.
-
Use cautiously with renal impairment, pregnancy, lactation, upper GI problems, oral surgery.
Available Forms
Tablets—5, 30, 35, 75 (CAN), 150 mg; DR tabletsDNC—35 mg
Dosages
Adults
-
Treatment and prevention of postmenopausal osteoporosis: 5 mg PO once daily taken in an upright position with 6–8 oz of water at least 30 min before or after any other beverage or food. For postmenopausal osteoporosis, may switch to 35-mg tablet or 35-mg DR tablet taken PO once per wk or 75 mg PO taken on 2 consecutive days each mo (total of 2 tablets per mo) or one 150-mg tablet PO per mo.
-
Treatment or prevention of glucocorticoid osteoporosis: 5 mg/day PO.
-
Paget disease: 30 mg PO once daily for 2 mo taken in an upright position with 6–8 oz of plain water at least 30 min before or after any other beverage or food; may retreat after at least a 2-mo post-treatment period if indicated.
-
To increase bone mass in men with osteoporosis: 35 mg PO once/wk.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
